Volume 2.18 | May 13

Mammary Cell News 2.18 May 13, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe


Breast Cancer Gene Clue Discovery
Five genetic clues as to why some women have a family history of breast cancer have been identified by UK researchers. [Press release from British Broadcasting Corporation discussing online prepublication in Nature Genetics]



STEMCELL Technologies with The Jackson Laboratories offers:

Mammary Stem Cell Training Course
Two-Day Lecture and Laboratory Series
June 29-30, 2010
The Jackson Laboratories, Maine, USA


Estrogen Receptor Status of HER2+ Breast Cancer Correlates with Response to Anti-HER Therapies
An international team of researchers has discovered molecular evidence that may explain why some women with HER2 over-expressing breast cancer do not respond to drugs designed to target this important molecule. [Press release from European Society for Medical Oncology discussing research presented at the IMPAKT Breast Cancer Conference]

Simple Gene Test Identifies Clinically Important Sub-Types of Breast Cancer
A simple genetic test that uses just three genes is among the most effective means of classifying breast cancer into sub-types, US researchers report. The findings are a significant step in bringing more personalized treatment into breast cancer. [Press release from European Society for Medical Oncology discussing research presented at the IMPAKT Breast Cancer Conference]

Survival in Metastatic Breast Cancer Directly Linked to Circulating Tumor Cells
A new study of metastatic breast cancer shows that the number of circulating tumor cells patients have in their blood directly correlates with the length of their survival. [Press release from European Society for Medical Oncology discussing research presented at the IMPAKT Breast Cancer Conference]

Genome Breakthrough Allows Scientists to Identify and Profile Tumor Cells from Very Small Samples
Researchers have developed a powerful new technique for analyzing the genome of single tumor cells. The breakthrough allows them to study in fine detail the biology of how tumors develop and has the potential to help doctors identify dangerous tumor cells from small samples such as fine-needle biopsies from the prostate or a non-invasive lesion in the breast. [Press release from European Society for Medical Oncology discussing research presented at the IMPAKT Breast Cancer Conference]


CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)


Genome-Wide Association Study Identifies Five New Breast Cancer Susceptibility Loci
To identify common breast cancer susceptibility alleles, researchers conducted a genome-wide association study in which 582,886 single-nucleotide polymorphisms were genotyped in 3,659 cases with a family history of the disease and 4,897 controls. [Nat Genet]

Pathways of Proliferation and Antiapoptosis Driven in Breast Cancer Stem Cells by Stem Cell Protein Piwil2
In this study, researchers documented specific expression of the stem cell protein Piwil2 in breast cancer with predominant expression in breast cancer stem cells. [Cancer Res]

Pathway Analysis of Breast Cancer Genome-Wide Association Study Highlights Three Pathways and One Canonical Signaling Cascade
Researchers applied a pathway-based approach to the breast cancer genome-wide association studies data of the National Cancer Institute Cancer Genetic Markers of Susceptibility project that includes 1,145 cases and 1,142 controls. [Cancer Res]

Extranuclear Functions of ER Impact Invasive Migration and Metastasis by Breast Cancer Cells
Researchers examined the mechanism and significance of ER-PELP1-mediated extranuclear signals in the cytoskeletal remodeling and metastasis. [Cancer Res]

HEXIM1 Modulates Vascular Endothelial Growth Factor Expression and Function in Breast Epithelial Cells and Mammary Gland
Researchers demonstrate that hexamethylene bisacetamide-inducible protein 1 (HEXIM1) regulates estrogen-induced VEGF transcription through inhibition of estrogen receptor-alpha recruitment to the VEGF promoter in a P-TEFb-independent manner in MCF-7 cells. [Oncogene]

Mechanism of Inhibition of MMTV-Neu and MMTV-Wnt1 Induced Mammary Oncogenesis by RARalpha Agonist AM580
The anticancer effect of retinoic acid receptor (RAR) alpha, together with the newly discovered pro-proliferative role of RARgamma, suggests that specific activation of RARalpha and inhibition of RARgamma might be effective in breast cancer therapy. [Oncogene]

An Oncogenic Role of eIF3e/INT6 in Human Breast Cancer
Using immunohistochemical analysis of 81 primary breast cancers, researchers found that high tumor grade correlated significantly with elevated cytoplasmic eukaryotic translation initiation factor 3 (eIF3e) level in epithelial tumor cells. [Oncogene]

Persistent Expression of Biologically Active Anti-HER2 Antibody by AAVrh.10-Mediated Gene Transfer
Researchers hypothesized that a single adeno-associated virus-mediated genetic delivery of an anti-HER2 antibody should be effective in mediating long-term production of anti-HER2 and in suppressing the growth of human tumors in a xenograft model in nude mice. [Cancer Gene Ther]


Classical Cyclophosphamide, Methotrexate, and Fluorouracil Chemotherapy Is More Effective in Triple-Negative, Node-Negative Breast Cancer: Results From Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer
Patients enrolled in International Breast Cancer Study Group Trials VIII and IX with node-negative, operable breast cancer and centrally assessed estrogen receptor, progesterone receptor, and HER2 were included (n = 2,257). The trials compared three or six courses of adjuvant classical cyclophosphamide, methotrexate, and fluorouracil with or without endocrine therapy versus endocrine therapy alone. [J Clin Oncol]

Intense Dose-Dense Sequential Chemotherapy With Epirubicin, Paclitaxel, and Cyclophosphamide Compared With Conventionally Scheduled Chemotherapy in High-Risk Primary Breast Cancer: Mature Results of an AGO Phase III Study
In this randomized, phase III trial, a total of 1,284 eligible patients with four or more involved axillary lymph nodes were randomly assigned to receive intense dose-dense sequential epirubicin, paclitaxel, and cyclophosphamide every 2 weeks or conventionally scheduled epirubicin/cyclophosphamide followed by paclitaxel every three weeks. [J Clin Oncol]


Watson Confirms EVISTA(R) Patent Challenge
Watson Pharmaceuticals, Inc. confirmed that its subsidiary, Watson Laboratories, Inc. filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market a raloxifene hydrochloride tablet. Watson’s raloxifene hydrochloride tablet is a generic version of Eli Lilly’s EVISTA(R). [Watson Pharmaceuticals, Inc. Press Release]

Medifocus Inc. Announces That It Has Received Approval for Its Amended Phase III Clinical Trial for Treatment of Breast Cancer from Health Canada
Medifocus Inc. is pleased to announce that it has received approval from Health Canada to amend its pivotal Phase III study design and clinical protocol to conform to the study design and clinical protocol as approved by the Food and Drug Administration in the USA for the Company’s pivotal Phase III clinical trial on treatment of breast cancer. [BusinessWire]

Georgia Hospital Offers to Repeat Hundreds of Mammograms After Employee Error
A Georgia hospital is in hot water after it was discovered that the results of 900 mammograms administered to women throughout last year and early 2010 may be inaccurate. [FierceHealthcare]


NIH Starts to Flesh out Drug Development Program
Lawmakers began discussing the details of a newly created drug development program at the National Institutes of Health (NIH). NIH Director Francis Collins told a Senate panel that he’s eager to get started-once the program has a budget. [National Institutes of Health, United States]

NSF to Ask Every Grant Applicant for Data Management Plan
Scientists seeking funding from the National Science Foundation (NSF) will soon need to spell out how they plan to manage the data they hope to collect. It’s part of a broader move by NSF and other federal agencies to emphasize the importance of community access to data. [National Science Foundation, United States]

Enhancing Peer Review: Expectation for Service on NIH Peer Review and Advisory Groups [National Institutes of Health, United States]

Request for Information: Scientific and Regulatory Issues to be Explored at an Upcoming Pluripotent Stem Cell Workshop Involving NIH and FDA (NOT-NS-10-016) [National Institutes of Health, United States]

Drug Safety and Risk Management Advisory Committee; Notice of Meeting (Docket No. FDA-2010-N-0001) [Food and Drug Administration, United States]

Agency Information Collection Activities; Proposed Collection; Comment Request; Experimental Study of Patient Information Prototypes (Docket No. FDA-2010-N-0184) [Food and Drug Administration, United States]


Breast Cancer Research 2010 Conference
May 18, 2010
London, United Kingdom

American Society of Clinical Oncology (ASCO) Annual Meeting 2010
June 4-8, 2010
Chicago, United States

Gordon Research Conference: Mammary Gland Biology
June 6-11, 2010
Lucca (Barga), Italy

12th Milan Breast Cancer Conference
June 16-18, 2010
Milan, Italy

International Society for Stem Cell Research (ISSCR) 8th Annual Meeting
June 16-19, 2010
San Francisco, United States

The 21st Meeting of the European Association for Cancer Research (EACR)
June 26-29, 2010
Oslo, Norway

United Kingdom National Stem Cell Network (UKNSCN) Third Annual Scientific Conference
July 12-14, 2010
Nottingham, United Kingdom

Stem Cells USA & Regenerative Medicine Congress 2010
September 13-15, 2010
Philadelphia, United States

15th Congress of the European Society of Surgical Oncology (ESSO)
September 15-17, 2010
Bordeaux, France

2010 World Cancer Congress
August 18-21, 2010
Shenzhen, China

35th European Society for Medical Oncology (ESMO) Congress
October 8-12, 2010
Milan, Italy

International Symposium on Breast Cancer Prevention: Nutrition, Communications, Public Policy
October 18-19, 2010
West Lafayette, United States

6th National Cancer Research Institute (NCRI) Conference
November 7-10, 2010
Liverpool, United Kingdom


Business Development Manager Europe – Cell Therapy Products (Pall Corporation)

Sr. Product Support and Training Specialist (CardianBCT)

Manager/Sr. Manager, Therapeutic Cell Solutions, Process Development (Lonza)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.
Visit here to post your career opportunities.

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Learn more about Mammary Cell News: Archives  |  Events  |  Subscribe  |  Contact Us